Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

108.06
-0.0800-0.07%
Post-market: 108.060.00000.00%19:30 EDT
Volume:272.52K
Turnover:29.38M
Market Cap:1.01B
PE:87.56
High:108.33
Open:108.14
Low:107.29
Close:108.14
52wk High:118.00
52wk Low:90.60
Shares:9.39M
Float Shares:9.39M
Volume Ratio:0.61
T/O Rate:2.90%
Dividend:2.18
Dividend Rate:2.02%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):139.17

Loading ...

OverviewCompanyNewsFilings

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell

Dow Jones
·
Sep 30

Marka S.A. Pays Twelfth Installment Under Amended Bondholder Arrangement

TIPRANKS
·
Sep 30

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

TIPRANKS
·
Sep 30

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Reuters
·
Sep 30

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS
·
Sep 30

Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study

Reuters
·
Sep 30

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS
·
Sep 30

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

Reuters
·
Sep 30

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live
·
Sep 30

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS
·
Sep 30

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Reuters
·
Sep 30

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Sep 30

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Sep 30

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Sep 30
More